Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer - PubMed (original) (raw)
Clinical Trial
. 1997 Nov 19;89(22):1673-82.
doi: 10.1093/jnci/89.22.1673.
J Dignam, N Wolmark, A DeCillis, B Emir, D L Wickerham, J Bryant, N V Dimitrov, N Abramson, J N Atkins, H Shibata, L Deschenes, R G Margolese
Affiliations
- PMID: 9390536
- DOI: 10.1093/jnci/89.22.1673
Clinical Trial
Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
B Fisher et al. J Natl Cancer Inst. 1997.
Abstract
Background: The B-20 study of the National Surgical Adjuvant Breast and Bowel Project (NSABP) was conducted to determine whether chemotherapy plus tamoxifen would be of greater benefit than tamoxifen alone in the treatment of patients with axillary lymph node-negative, estrogen receptor-positive breast cancer.
Methods: Eligible patients (n = 2306) were randomly assigned to one of three treatment groups following surgery. A total of 771 patients with follow-up data received tamoxifen alone; 767 received methotrexate, fluorouracil, and tamoxifen (MFT); and 768 received cyclophosphamide, methotrexate, fluorouracil, and tamoxifen (CMFT). The Kaplan-Meier method was used to estimate disease-free survival, distant disease-free survival, and survival. Reported P values are two-sided.
Results: Through 5 years of follow-up, chemotherapy plus tamoxifen resulted in significantly better disease-free survival than tamoxifen alone (90% for MFT versus 85% for tamoxifen [P = .01]; 89% for CMFT versus 85% for tamoxifen [P = .001]). A similar benefit was observed in both distant disease-free survival (92% for MFT versus 87% for tamoxifen [P = .008]; 91% for CMFT versus 87% for tamoxifen [P = .006]) and survival (97% for MFT versus 94% for tamoxifen [P = .05]; 96% for CMFT versus 94% for tamoxifen [P = .03]). Compared with tamoxifen alone, MFT and CMFT reduced the risk of ipsilateral breast tumor recurrence after lumpectomy and the risk of recurrence at other local, regional, and distant sites. Risk of treatment failure was reduced after both types of chemotherapy, regardless of tumor size, tumor estrogen or progesterone receptor level, or patient age; however, the reduction was greatest in patients aged 49 years or less. No subgroup of patients evaluated in this study failed to benefit from chemotherapy.
Conclusions: Findings from this and other NSABP studies indicate that patients with breast cancer who meet NSABP protocol criteria, regardless of age, lymph node status, tumor size, or estrogen receptor status, are candidates for chemotherapy.
Comment in
- Adjuvant therapy for early breast cancer: a time to refine.
Powles TJ. Powles TJ. J Natl Cancer Inst. 1997 Nov 19;89(22):1652-4. doi: 10.1093/jnci/89.22.1652. J Natl Cancer Inst. 1997. PMID: 9390527 No abstract available. - Re: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer.
Atkins CD. Atkins CD. J Natl Cancer Inst. 1998 Mar 18;90(6):468-9. doi: 10.1093/jnci/90.6.468. J Natl Cancer Inst. 1998. PMID: 9521174 No abstract available.
Similar articles
- Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Fisher B, et al. Lancet. 2004 Sep 4-10;364(9437):858-68. doi: 10.1016/S0140-6736(04)16981-X. Lancet. 2004. PMID: 15351193 Clinical Trial. - Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Fisher B, et al. J Clin Oncol. 1996 Jul;14(7):1982-92. doi: 10.1200/JCO.1996.14.7.1982. J Clin Oncol. 1996. PMID: 8683228 Clinical Trial. - Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer.
Fisher B, Jeong JH, Dignam J, Anderson S, Mamounas E, Wickerham DL, Wolmark N. Fisher B, et al. J Natl Cancer Inst Monogr. 2001;(30):62-6. doi: 10.1093/oxfordjournals.jncimonographs.a003463. J Natl Cancer Inst Monogr. 2001. PMID: 11773294 - Adjuvant treatment in node-negative, postmenopausal breast cancer.
Hutchins LF, Arick CL. Hutchins LF, et al. Cancer Invest. 2001;19(7):706-22. doi: 10.1081/cnv-100106146. Cancer Invest. 2001. PMID: 11577812 Review. No abstract available.
Cited by
- 70-Gene signature-guided adjuvant systemic treatment adjustments in early-stage ER+ breast cancer patients: 7-year follow-up of a prospective multicenter cohort study.
Verreck EEF, Kuijer A, van Steenhoven JEC, Volders JH, van der Velden AWG, Siesling S, Timmer-Bonte ANH, Smilde TJ, Imholz ALT, Blanken-Peeters CFJM, de Valk B, Vrijaldenhoven S, Lastdrager WB, Haringhuizen AW, Hunting JCB, Hovenga S, Nieboer P, Zuetenhorst HM, Tetteroo GWM, Smorenburg CH, van Maaren MC, van Dalen T. Verreck EEF, et al. Breast Cancer Res Treat. 2024 Sep 30. doi: 10.1007/s10549-024-07496-3. Online ahead of print. Breast Cancer Res Treat. 2024. PMID: 39349887 - Sequential versus concurrent adjuvant chemo-endocrine therapy for HR+ early breast cancer: a systematic review and Bayesian network meta-analysis.
Li T, Shan Z, Shi Y, Kuang X, Yu L, Tang SC, Shao N, Lin Y. Li T, et al. Transl Breast Cancer Res. 2022 Jan 31;3:8. doi: 10.21037/tbcr-21-3. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751511 Free PMC article. - Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center.
Deme D, Tamaskovics BF, Jammoul N, Kovács S, Kayode EO, Grice JW, Telekes A. Deme D, et al. Pathol Oncol Res. 2024 Apr 16;30:1611735. doi: 10.3389/pore.2024.1611735. eCollection 2024. Pathol Oncol Res. 2024. PMID: 38689824 Free PMC article. - Application of a 21-Gene Recurrence Score in a Swiss Single-Center Breast Cancer Population: A Comparative Analysis of Treatment Administration before and after TAILORx.
Chiru ED, Oseledchyk A, Schoetzau A, Kurzeder C, Mosimann R, Vetter M, Grašič Kuhar C. Chiru ED, et al. Diagnostics (Basel). 2023 Dec 31;14(1):97. doi: 10.3390/diagnostics14010097. Diagnostics (Basel). 2023. PMID: 38201405 Free PMC article. - Validation of the RSClin risk calculator in the National Cancer Data Base.
Vannier AGL, Dhungana A, Zhao F, Chen N, Shubeck S, Hahn OM, Nanda R, Jaskowiak NT, Fleming GF, Olopade OI, Pearson AT, Huo D, Howard FM. Vannier AGL, et al. Cancer. 2024 Apr 15;130(8):1210-1220. doi: 10.1002/cncr.35163. Epub 2023 Dec 26. Cancer. 2024. PMID: 38146744
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials